| Name | Title | Contact Details |
|---|
IRIDEX Corporation is a worldwide leader in developing, manufacturing, marketing and selling innovative and cost-effective medical laser systems. The company has the largest global installed base of solid-state lasers and focuses on developing laser products that are clinically effective, reliable, portable, versatile, and affordable.
Integrated Medical Systems International is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BAROnova, Inc., founded in 2006 and based in Goleta, CA, is a clinical-stage medical-device company focused on developing non-surgical non-pharmacologic devices to induce weight loss.
Fisher and Paykel Healthcare Corporation Limited is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.